Precision Medicine Targeting Metabolic Disorders Like Type 2 Diabetes, Obesity, Dylipidemia, and More
Aracea Therapeutics is developing a new therapeutic approach to slowing or halting disorders resulting from poor glucose control and excess calories such as type 2 diabetes, obesity, and related metabolic diseases.
Our innovations focus on energy expenditure and glycemic control by harnessing the recent revolution in human genetics and functional genomics.
Advanced Analysis
Genes to Medicine
Patient-Focused Therapy
Advanced Analysis
Dramatic advances in DNA sequencing and antisense and gene editing technologies, such as Next Generation Sequencing (NGS) and CRISPR, now enable us to seek and identify genes related to disease and turn these genes into medicines. Together with existing knowledge and data, we are conducting genetic screens and studying natural human genetic variation related to glucose control.
Genes to Medicine
Gene sequences determined to influence metabolic disease are studied. Advances in genome editing made possible by CRISPR allow us to find superior solutions.
We are conducting research and development across technology platforms – gene therapy, antisense therapy, in vivo genome regulation, and cell therapy – to resolve the underlying genetic cause of metabolic syndrome and to design the best therapeutic approach.
Patient-Focused Therapy
Using our extensive scientific background and technical expertise in this field, and strong desire for results, we are now developing new, lasting therapies that will improve the health of people with poor glycemic control.
Our therapies will benefit the nearly 30 million adults living with type 2 diabetes, as well as the estimated 84 million prediabetic adults in the United States and around the world. They also promise to benefit other diseases that result from poor glycemic control.